|
BGNE | Beigene, Ltd. |
|
|
BGNE | Beigene, Ltd. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.03 |
| Leverage | 42.52% |
| Market Cap | $ 313.9B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -390.7m |
| Margin | -9.41% |
BeiGene, Ltd. discovers, develops, manufactures and markets cancer therapeutics drugs in the Peoples Republic of China and the United States. The company is headquartered in Beijing, the Peoples Republic of China.